Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Q-VD-OPH (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a pan-caspase inhibitor with potent antiapoptotic properties.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,000 | |||
5 mg | 在庫あり | ¥ 20,000 | |||
10 mg | 在庫あり | ¥ 34,000 | |||
25 mg | 在庫あり | ¥ 54,500 | |||
50 mg | 在庫あり | ¥ 84,500 | |||
100 mg | 在庫あり | ¥ 125,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 22,500 |
説明 | Q-VD-OPH (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a pan-caspase inhibitor with potent antiapoptotic properties. |
ターゲット&IC50 | Caspase-1:25 nM-400 nM, Caspase-8:25 nM-400 nM, Caspase-9:25 nM-400 nM, Caspase-3:25 nM-400 nM |
In vitro | Q-VD-OPh (5-100 μM) potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. [2] Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro. [4] |
In vivo | Q-VD-OPh inhibits caspase-1 activity, IL-18 protein expression, and neutrophil infiltration during ischemic ARF in mice. [3] In vivo, caspase inhibition by Q-VD-OPh provides protection from virus-induced myocardial injury, with a significant reduction in caspase-3 activity. [4] In TgCRND8 mice, Q-VD-OPh inhibits caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage. [5] |
キナーゼ試験 | Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200?000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1]. |
細胞研究 | Caspase inhibitors are added at the indicated concentrations 30 minutes prior to the addition of apoptotic stimuli. Viability and cell number are determined by trypan blue exclusion from three random fields of greater than 200 cells/field. All experiments are performed a minimum of three times.(Only for Reference) |
別名 | Quinoline-Val-Asp-Difluorophenoxymethylketone |
分子量 | 513.5 |
分子式 | C26H25F2N3O6 |
CAS No. | 1135695-98-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 100 mg/mL (194.75 mM)
DMSO: 50 mg/mL (97.37 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Q-VD-OPH 1135695-98-5 Apoptosis Microbiology/Virology Proteases/Proteasome HIV Protease Caspase QVD-OPH QVDOPH inhibit Quinoline-Val-Asp-Difluorophenoxymethylketone Human immunodeficiency virus Inhibitor HIV Q VD OPH inhibitor